Clinical trial of PEG-rhGH in the treatment of children with idiopathic short stature
10.13699/j.cnki.1001-6821.2024.18.016
- VernacularTitle:PEG-rhGH治疗特发性矮小症患儿对生长速率影响的临床研究
- Author:
Xin WANG
1
;
Qian DENG
;
Min LI
;
Juan-Juan WANG
Author Information
1. 安徽省儿童医院内分泌代谢科,安徽合肥 230011
- Keywords:
polyethylene glycol recombinant human growth hormone;
idiopathic short stature;
growth velocity;
bone age
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(18):2685-2689
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore growth velocity(GV)and analyze its influencing factors in children with idiopathic short stature(ISS)after treatment with polyethylene glycol recombinant human growth hormone(PEG-rhGH).Methods The clinical data of children with ISS were retrospectively analyzed.All children were given subcutaneous injection of PEG-rhGH(0.16-0.17 mg·kg-1 each week)at periumbilical,lateral upper arm and thigh sites for 1 year.The differences in growth parameters before and after treatment were observed,and GV after treatment was recorded.The influencing factors of GV at 1 year after treatment were analyzed by multivariate stepwise linear regression analysis.Results Before and after 1 year of treatment,height(Ht)was(109.51±12.59)and(123.16±13.07)cm,height standard deviation scores(HtSDS)were-2.24±0.25 and-1.71±0.21,GV levels were(3.81±0.52)and(9.88±1.04)cm·year-1,levels of 25-hydroxy-vitamin-D[25(OH)D]were(27.19±3.14)and(33.05±3.46)ng·mL-1,levels of propeptide of type I procollagen(PINP)were(490.29±54.30)and(598.45±57.18)μg·L-1,levels of insulin-like growth factor-1(IGF-1)were(114.86±19.14)and(213.73±20.03)ng·mL-1,levels of insulin-like growth factor binding protein-3(IGFBP-3)were(6 817.27±716.30)and(7 230.39±721.45)ng·mL-1,the differences were statistically significant(all P＜0.05).Before treatment,chronological age(CA),bone age(BA),bone age delay(BAD),bone age index(BAI)and mid-parental height(MPH)were(8.05±1.09)years,(7.14±1.01)years,(-0.98±0.18)years,0.86±0.12 and(167.31±5.73)cm,respectively.Pearson correlation analysis showed that GV level after treatment was negatively correlated with CA,BA and BAI before treatment,while positively correlated with BAD and MPH before treatment(P＜0.05).The results of multivariate stepwise linear regression analysis showed that high levels of CA,BA and BAI before treatment were risk factors of low GV level after PEG-rhGH treatment,while high levels of BAD and MPH before treatment were protective factors.Conclusion GV response is good in ISS children with low age at the beginning of PEG-rhGH treatment and bone age.Genetic targeted height can affect GV after treatment.
